Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341311 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Marizomib + Panobinostat for Children With DIPG
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04341311 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 4 participants.
The verdict
NCT04341311, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The names of the study drugs involved in this study are: * Marizomib * Panobinostat
Interventions
- DRUG Panobinostat
- DRUG Marizomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2024-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04341311
The ClinicalTrials.gov registry entry for NCT04341311 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Panobinostat is the first listed.
NCT04341311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04341311 about?
NCT04341311 is a clinical study titled "Phase I Study of Marizomib + Panobinostat for Children With DIPG". This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The names of the study drugs involved in this study are: * Marizomib * Panobinostat
What is the current status of trial NCT04341311?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-08-10. Estimated completion is 2024-02-14.
What interventions are being tested in trial NCT04341311?
The interventions under investigation include: Panobinostat (DRUG), Marizomib (DRUG).
Who is sponsoring clinical trial NCT04341311?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.